Nuvisan logo
  • contact us navContact Us
  • search navSearch

Pharmacology

Our experienced team of specialists offers high-quality pharmacology services, from target identification, validation and deconvolution to translational research. With extensive industry experience across target classes and modalities, we implement novel mechanistic cell-based assays and in vivo pharmacology models. Our diverse portfolio of models supports a deep exploration and understanding of drug targets and disease biology, as well as the mode-of-action of your drug candidates. We make use of state-of-art in vitro and in vivo models, combined with an extensive assay technology platform for broad characterisation. 
Scientist using a computer for immunofluorescence microscopy in a lab

Target identification, validation and deconvolution

Our experienced scientists collaborate with your team using advanced functional genomics and in vitro/in vivo assay platforms. This enables us to identify, validate and deconvolute disease-relevant targets, providing a strong foundation for your drug discovery and development.

learn more
Human immune cells stained with a fluorescently labelled antibody

Cell-based assays

Cell-based assays are crucial for drug discovery and development, providing a realistic biological context. Our biology team offers disease-relevant in vitro and in vivo models to identify leads and targets, including high-throughput formats using specialised chemical libraries. Additionally, these models help determine the structure-activity relationships of drug candidates, validate signaling pathways and mechanisms of action and identify biomarker candidates to support the success of the project.

learn more
Ex vivo analysis, in vivo study, µCT imaging

In vivo pharmacology

Assessing efficacy and pharmacokinetics in living organisms, in vivo pharmacology helps provide insights into drug interactions, metabolism and excretion, while identifying potential biomarkers and side effects. We offer disease-relevant models for various indications and provide in vivo biodistribution studies for lipid nanoparticles and adeno-associated viruses.

learn more

Frequently asked questions (FAQs)

  • How do you help ensure a proposed target is truly disease-relevant?
    We combine functional genomics with fit-for-purpose in vitro and in vivo assay platforms to test causality rather than correlation. This typically includes perturbation approaches, such as gene modulation, pathway and phenotype readouts, and orthogonal confirmation to clarify mechanisms. The aim is to build a robust evidence base that links target modulation to meaningful biology and informs early translation strategy.
  • What types of cell-based assays can you develop, and how do you tailor them to a project?
    We design cell-based assays around the biology that best addresses your research question, whether this relates to mechanistic target engagement, pathway signalling, functional phenotypes or disease-relevant responses. We select and optimise assays to support decision-making, such as potency and efficacy ranking, selectivity assessment and MoA differentiation. Assays can also be developed for the throughput and robustness needed for screening, profiling or lead optimisation.
  • How do you approach in vivo study design to maximise translational value?
    We start with the intended clinical question and work backwards to select the most relevant models, endpoints and biomarkers. Study designs are tailored to capture pharmacodynamic effects, exposure–response relationships and meaningful efficacy readouts. We also align sampling and bioanalytical plans to support mechanistic interpretation and reduce iteration.
  • How do you integrate results across assays to guide go/no-go decisions?
    We build a clear line of evidence across assay tiers by linking target engagement to functional cellular outcomes and then to in vivo pharmacology endpoints. This helps distinguish true biology-driven signals from assay artefacts, supports confidence in the MoA and improves candidate selection by focusing on consistency, reproducibility and exposure-aligned efficacy rather than isolated readouts.

Contact us

Nuvisan is committed to protecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:
You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Email us

hello@nuvisan.com

Talk to us

talk icon
+49 731 9840 0 

Our locations

location icon

Neu-Ulm (headquarters)

Wegenerstrasse 13

89231 Neu-Ulm

Germany

Berlin

Muellerstrasse 178

13353 Berlin

Germany

Sophia Antipolis

2400 route des Colles

06410 Biot

France

Grafing

Am Feld 32

85567 Grafing

Germany

Waltrop

Im Wirrigen 25

45731 Waltrop

Germany

For concerns about pharmaceuticals or adverse drug-related events, contact us at: complaints@nuvisan.com
 
v.1.1.1399